Comparison Of Intrathecal Bupivacaine With Nalbuphine And Bupivacaine With Fentanyl In Inguinal Hernia Surgery
DOI:
https://doi.org/10.48165/ijabms.2020.22214Keywords:
Bupivacaine, Fentanyl, Nalbuphine, Spinal Anaesthesia, Inguinal Hernia SurgeryAbstract
CONTEXT Opioids as an adjuvant to hyperbaric Bupivacaine improves perioperative analgesia with minimal side effects. AIM-The aim of the study is to compare the effect of intrathecal Nalbuphine and Fentanyl as adjuvants to hyperbaric Bupivacaine on onset and duration of sensory blockade, onset and duration of motor blockade, two segment sensory regression time, duration of effective postoperative analgesia and incidence of side effects. STUDY DESIGN Prospective observational study ETHICAL ASPECT AND METHODS After all ethical committee clearance and written informed consent, 60 patients of ASA grade I and II undergoing inguinal hernia surgery will be randomly divided into two groups: Group I – 0.5 % Bupivacaine(heavy) 3 ml + Nalbuphine 0.1 ml (1 mg) and Group II – 0.5% Bupivacaine(heavy) 3 ml + Fentanyl 0.5 ml (25 µg). RESULT There was no significant difference in onset ofsensory and motor blockade.Duration of sensory blockade was significantly prolonged (111.42 ± 9.21 min) in Group I than in Group II (102.32 ± 6.45 min) and duration of motor block was significantly extended in patients of Group I(144.65± 15.12 min) than Group II (130.42 ±11.12 min). The duration of effective analgesia was significantly more in group I than group II, with no significant side effects. CONCLUSION-1 mg Nalbuphine in 3 ml 0.5% hyperbaric Bupivacaine in patients increases the duration of sensory and motor block as compared to Fentanyl as well as provides effective analgesia time more than Fentanyl in patients scheduled for inguinal hernia surgery under subarachnoid block.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Sushmita K Shah, Drashti A Vavadia, Vidhi A Gajjar, Pinal Bhikadiya , Aishwarya Raj, Vibhuti Shah
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.